S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 104 000 KRW -0.76% Market Closed
Market Cap: 2.4T KRW
Have any thoughts about
Sam Chun Dang Pharm Co Ltd?
Write Note

Sam Chun Dang Pharm Co Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sam Chun Dang Pharm Co Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Operating Expenses
-â‚©94.5B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
-8%
Yuhan Corp
KRX:000100
Operating Expenses
-â‚©603B
CAGR 3-Years
0%
CAGR 5-Years
-8%
CAGR 10-Years
-10%
SK Biopharmaceuticals Co Ltd
KRX:326030
Operating Expenses
-â‚©358.3B
CAGR 3-Years
-11%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Operating Expenses
-â‚©198.6B
CAGR 3-Years
-26%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
Hanmi Pharm Co Ltd
KRX:128940
Operating Expenses
-â‚©619.1B
CAGR 3-Years
-9%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
C
Celltrion Pharm Inc
KOSDAQ:068760
Operating Expenses
-â‚©85B
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
-9%
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
2.4T KRW
Industry
Pharmaceuticals

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.

Intrinsic Value
11 241.66 KRW
Overvaluation 89%
Intrinsic Value
Price
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Operating Expenses?
Operating Expenses
-94.5B KRW

Based on the financial report for Sep 30, 2024, Sam Chun Dang Pharm Co Ltd's Operating Expenses amounts to -94.5B KRW.

What is Sam Chun Dang Pharm Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-8%

Over the last year, the Operating Expenses growth was -12%. The average annual Operating Expenses growth rates for Sam Chun Dang Pharm Co Ltd have been 2% over the past three years , -3% over the past five years , and -8% over the past ten years .

Back to Top